Fedha

Hisa unazofuatilia
Kwa nini EVT imeongezeka kwa 2.05%?
Fahamu zaidi
EVT:FRA
Evotec SE
€ 2.89
+2.05%
(+0.058) Siku 1
8 Okt, 08:01:17 GMT +2  ·   EUR
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya EVT...
Fungua
€ 2.89
Juu
€ 2.89
Chini
€ 2.89
Mtaji wa soko
515.27M
Wastani wa kiasi cha mauzo
elfu 4.65
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 7.49
Chini kwa wiki 52
€ 2.73
EPS
-€ 1.11
Hisa za wawekezaji
148.72M
Idadi ya wafanyakazi
elfu 4
Fungua
€ 2.89
Juu
€ 2.89
Chini
€ 2.89
Mtaji wa soko
515.27M
Wastani wa kiasi cha mauzo
elfu 4.65
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 7.49
Chini kwa wiki 52
€ 2.73
EPS
-€ 1.11
Hisa za wawekezaji
148.72M
Idadi ya wafanyakazi
elfu 4
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Kuhusu Evotec SE
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazielfu 4.46
Lilianzishwa1993
Makao makuu-
Sekta-
Ripoti za awaliThamani zote katika EUR
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika EUR
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
163.89M
253.27M
156.64M
143.48M
Gharama ya bidhaa zilizouzwa
163.95M
174.81M
158.21M
145.06M
Gharama ya mapato
163.95M
174.81M
158.21M
145.06M
Gharama za utafiti na maendeleo
8.71M
9.83M
10.08M
10.26M
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
42.31M
44.35M
43.79M
39.29M
Gharama ya uendeshaji
43.53M
55.25M
44.85M
87.74M
Jumla ya gharama za uendeshaji
207.48M
230.06M
203.07M
232.80M
Mapato ya uendeshaji
-43.59M
23.21M
-46.42M
-89.32M
Mapato mengine yasiyo ya uendeshaji
1.19M
-33.96M
1.89M
elfu -839.00
EBT ikijumuisha vipengee visivyo vya kawaida
-42.96M
29.46M
-122.18M
-48.12M
EBT bila kujumuisha vipengee visivyo vya kawaida
-43.36M
18.35M
-47.40M
-94.00M
Gharama ya kodi ya mapato
elfu 127.00
14.84M
elfu -244.00
-1.47M
Kiwango cha kodi kinachotumika
-0.30%
50.37%
0.20%
3.06%
Gharama nyingine za uendeshaji
-7.50M
1.07M
-9.02M
38.20M
Mapato halisi
-43.09M
14.62M
-121.94M
-46.65M
Kiwango cha faida halisi
-26.29%
5.77%
-77.84%
-32.51%
Mapato kwa kila hisa
-0.24
-
-
-
Mapato ya riba na uwekezaji
elfu 841.00
11.84M
-
-
Gharama ya riba
-2.28M
-
-2.58M
-2.97M
Jumla ya gharama halisi za riba
-1.44M
11.84M
-2.58M
-2.97M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
-18.27M
41.91M
-22.60M
-64.88M
Faida au hasara kutokana na uuzaji wa vipengee
-
-
-
-
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google